Background: apixaban (BMS-562247)(Eliquis®) is a novel, orally active, selective, direct,
reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was …

Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose …

Monitoring of anti-coagulation with the direct factor Xa inhibitor rivaroxaban is considered
unnecessary in a routine clinical setting. However, assessment of its anti-coagulant effect …

Many patients have a variety of prothrombotic risk factors or conditions, and these patients
are often given anticoagulant/antithrombotic treatment. Such treatments for thromboembolic …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

To improve existing strategies for the prevention and treatment of thromboembolic diseases,
new drugs targeting specifically clotting serine proteases (especially factor Xa [FXa] or …

Because their anticoagulant effect is dose predictable, steady, and little influenced by diet
and drugs, laboratory monitoring was deemed unnecessary in trials on venous and arterial …

Direct oral anticoagulants (DOACs) are a group of direct coagulation factor inhibitors
including both direct thrombin inhibitors and direct factor Xa inhibitors. These medications …

Abstract Background Oral factor Xa inhibitors (FXaI) can be administered in fixed doses
without the need for routine laboratory monitoring. Anti-Xa assays can estimate …

Background Traditional coagulation tests are included in emergency guidelines for
management of patients on direct oral anticoagulants (DOACs) who experience acute …